Is a liver attenuation 30 HU lower than the spleen on CT consistent with hepatic steatosis (fatty liver)?

Is a Liver 30 HU Lower Than Spleen Consistent with Fatty Liver?

Yes, a liver attenuation 30 HU lower than the spleen on unenhanced CT is highly consistent with moderate-to-severe hepatic steatosis and exceeds the diagnostic threshold by a substantial margin. 1

Diagnostic Thresholds on Unenhanced CT

According to the American College of Radiology 2023 guidelines, the following criteria establish hepatic steatosis on unenhanced CT:

• A liver-to-spleen attenuation difference >10 HU (with liver lower than spleen) diagnoses moderate-to-severe steatosis with 100% specificity and 82% sensitivity 1
• An attenuation ratio <1.0 (liver divided by spleen) confirms moderate-to-severe steatosis 1
• Absolute liver attenuation <40 HU correlates with ≥30% fat content (moderate steatosis) 1

Your finding of 30 HU difference far exceeds the 10 HU threshold, making the diagnosis of moderate-to-severe steatosis essentially certain. 1

Quantifying the Degree of Steatosis

The ACR provides specific attenuation values that correlate with progressive fat accumulation: 1

• 64.4 HU = 0% fat
• 59.1 HU = 1-25% fat (mild)
• 41.9 HU = 26-50% fat (moderate)
• 25.0 HU = >50% fat (severe)

A 30 HU difference between liver and spleen suggests the liver attenuation is markedly reduced, likely placing it in the moderate-to-severe steatosis range (26-50% or greater fat content). 1

Critical Caveats

This Only Applies to Unenhanced CT

• These diagnostic thresholds are ONLY valid on unenhanced (non-contrast) CT scans 1
• On contrast-enhanced CT, HU values are unreliable for steatosis quantification due to variability from contrast timing, injection site, protocol differences, and patient hemodynamics 1
• Research confirms that comparing liver to spleen on contrast-enhanced CT has only 30% specificity and 20% positive predictive value for fatty liver 2

Rule Out Alternative Diagnoses

Do not assume decreased liver attenuation always represents benign steatosis on contrast-enhanced studies—you must urgently exclude: 3

• Ischemic hepatitis (shock liver): appears as diffuse hepatic hypo-enhancement and carries high mortality if not recognized promptly 3
• Acute hepatitis: shows heterogeneous arterial enhancement, peri-portal hypoattenuation, perihepatic lymphadenopathy >7 mm, and ascites 3
• Cholestatic conditions: peri-portal edema can cause low attenuation 3

Clinical Management Algorithm

If This is Unenhanced CT:

1. Confirm moderate-to-severe hepatic steatosis (≥30% fat content) based on the 30 HU liver-spleen difference 1

2. Obtain comprehensive liver biochemistry: ALT, AST, GGT, alkaline phosphatase, bilirubin, albumin, and calculate AST:ALT ratio 4

3. Screen for metabolic syndrome components: assess BMI, type 2 diabetes, hypertension, dyslipidemia, and obtain detailed alcohol history 4

4. Calculate non-invasive fibrosis scores: FIB-4 index or NAFLD Fibrosis Score to stratify risk of advanced fibrosis 4

5. For intermediate/high-risk patients: obtain transient elastography with controlled attenuation parameter (CAP) for simultaneous assessment of steatosis severity and liver stiffness 4

6. Optimize metabolic conditions: aggressively manage diabetes, hypertension, and dyslipidemia 4

7. Consider hepatology referral if FIB-4 suggests intermediate-to-high risk of fibrosis or if two or more metabolic risk factors are present 4

If This is Contrast-Enhanced CT:

You cannot reliably diagnose or quantify steatosis using these measurements. 1 Instead:

• Evaluate for acute hepatic injury patterns: look for heterogeneous enhancement, peri-portal hypoattenuation, or diffuse hypo-enhancement suggesting ischemia 3
• If clinical suspicion for steatosis remains high, obtain either unenhanced CT or MRI without contrast for accurate fat quantification 1

Bottom Line

A 30 HU liver-spleen attenuation difference on unenhanced CT is diagnostic of moderate-to-severe hepatic steatosis (≥30% fat) with near-certainty, as it triples the established diagnostic threshold of 10 HU. 1 This finding warrants metabolic risk factor assessment, fibrosis risk stratification, and consideration of hepatology referral depending on the clinical context. 4